These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 7286031)

  • 21. In vitro studies on the pharmacological properties of diacetolol, the major metabolite of acebutolol in man.
    Borchard U; Hafner D; Hirth C
    Arch Int Pharmacodyn Ther; 1985 Jan; 273(1):4-17. PubMed ID: 2860878
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Pharmacokinetics of acebutolol].
    Collins RF
    Nouv Presse Med; 1975 Dec; 4(46 Suppl):3223-8. PubMed ID: 768905
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The beta-blocking effect of diacetolol in humans and its relationship to plasma levels.
    Flouvat B; Roux A; Delhotal B; Lemaigre D; Leroy M; Liot F
    Int J Clin Pharmacol Ther Toxicol; 1982 Aug; 20(8):358-61. PubMed ID: 6126441
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Acebutolol and oral surgery: plasma levels following a single oral dose.
    Fergusson NV; Dalgleish JG; Saunders DA
    Ann R Coll Surg Engl; 1985 Mar; 67(2):124-6. PubMed ID: 3883878
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical pharmacology of acebutolol.
    Ryan JR
    Am Heart J; 1985 May; 109(5 Pt 2):1131-6. PubMed ID: 2859776
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Plasma and urine concentrations of acebutolol and its acetyl metabolite in patients with renal functional impairment.
    Munn S; Bailey RR; Begg E; Ebert R; Ferry DG
    N Z Med J; 1980 Apr; 91(658):289-91. PubMed ID: 6930006
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Displacement of [3H]dihydroalprenolol binding from rat heart and lung by acebutolol, diacetolol and D-diacetolol.
    Pong SF; Tinkham CL
    J Pharm Pharmacol; 1983 Mar; 35(3):198-9. PubMed ID: 6132987
    [No Abstract]   [Full Text] [Related]  

  • 28. Systemic bioavailability of acebutolol in man.
    Roux A; Flouvat B; Fouache Y; Bourdarias JP
    Biopharm Drug Dispos; 1983; 4(3):293-7. PubMed ID: 6626703
    [No Abstract]   [Full Text] [Related]  

  • 29. Pharmacological properties of diacetolol (M & B 16,942), a major metabolite of acebutolol.
    Basil B; Jordan R
    Eur J Pharmacol; 1982 May; 80(1):47-56. PubMed ID: 6124437
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetics and multiple peaking of acebutolol enantiomers in rats.
    Piquette-Miller M; Jamali F
    Biopharm Drug Dispos; 1997 Aug; 18(6):543-56. PubMed ID: 9267686
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The pharmacokinetics of intravenous and oral sulpiride in healthy human subjects.
    Wiesel FA; Alfredsson G; Ehrnebo M; Sedvall G
    Eur J Clin Pharmacol; 1980 May; 17(5):385-91. PubMed ID: 7418717
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effect of hydralazine on the pharmacokinetics of three different beta adrenoceptor antagonists: metoprolol, nadolol, and acebutolol.
    Jack DB; Kendall MJ; Dean S; Laugher SJ; Zaman R; Tenneson ME
    Biopharm Drug Dispos; 1982; 3(1):47-54. PubMed ID: 6123352
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Blood plasma binding of acebutolol and diacetolol in man.
    Coombs TJ; Coulson CJ; Smith VJ
    Br J Clin Pharmacol; 1980 Apr; 9(4):395-7. PubMed ID: 7378256
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antihypertensive effect of diacetolol in essential hypertension.
    Thibonnier M; Flabeau C; Thouvenin M; Roux A; Flouvat B; Pasquier P; Menard J
    Br J Clin Pharmacol; 1982 Apr; 13(4):533-7. PubMed ID: 6121577
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetics of acebutolol enantiomers in humans.
    Piquette-Miller M; Foster RT; Kappagoda CT; Jamali F
    J Pharm Sci; 1991 Apr; 80(4):313-6. PubMed ID: 1865329
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Absolute bioavailability of chlorthalidone in man: a cross-over study after intravenous and oral administration.
    Fleuren HL; Thien TA; Verwey-van Wissen CP; van Rossum JM
    Eur J Clin Pharmacol; 1979 Feb; 15(1):35-50. PubMed ID: 421727
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Study of acebutolol dialysis and pharmacokinetic data in patients with renal insufficiency undergoing hemodialysis].
    Roux A; Aubert P; Guédon J; Flouvat B
    Nouv Presse Med; 1975 Dec; 4(46 Suppl):3228-33. PubMed ID: 1219629
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A comparative pharmacokinetic and pharmacodynamic study of conventional and sustained-release preparations of acebutolol in healthy volunteers.
    Fleurot O; Lecocq B; Lecocq V; Le Liboux A; Montay G; Frydman A; Jaillon P
    Fundam Clin Pharmacol; 1991; 5(7):601-9. PubMed ID: 1778538
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chronic subcutaneous treatment with acebutolol: haemodynamic effects and metabolism in spontaneously hypertensive rats.
    Heimburger M; Davy M; Midol-Monnet M; Beslot F; Cohen Y
    J Pharm Pharmacol; 1986 Sep; 38(9):699-702. PubMed ID: 2877074
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetics of single oral and multiple intravenous and oral administration of acebutolol enantiomers in a rat model.
    Mostafavi SA; Foster RT
    Biopharm Drug Dispos; 1998 Oct; 19(7):425-31. PubMed ID: 9818708
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.